Wave Life Sciences reported mixed Q3 2025 results, missing on revenue and EPS. Despite the financial miss, the biotech highlighted strong clinical progress for its obesity and AATD programs.
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
